RU2009109352A - Кристаллическая форма эпотилона в и ее применение в фармацевтических композициях - Google Patents
Кристаллическая форма эпотилона в и ее применение в фармацевтических композициях Download PDFInfo
- Publication number
- RU2009109352A RU2009109352A RU2009109352/04A RU2009109352A RU2009109352A RU 2009109352 A RU2009109352 A RU 2009109352A RU 2009109352/04 A RU2009109352/04 A RU 2009109352/04A RU 2009109352 A RU2009109352 A RU 2009109352A RU 2009109352 A RU2009109352 A RU 2009109352A
- Authority
- RU
- Russia
- Prior art keywords
- epothilone
- average
- strong
- crystalline form
- warm
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 5
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims abstract 12
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims abstract 10
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims abstract 10
- 201000010099 disease Diseases 0.000 claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 238000012986 modification Methods 0.000 claims abstract 6
- 230000004048 modification Effects 0.000 claims abstract 6
- 238000002441 X-ray diffraction Methods 0.000 claims abstract 4
- 230000002062 proliferating effect Effects 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 238000002425 crystallisation Methods 0.000 claims abstract 2
- 230000008025 crystallization Effects 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940011051 isopropyl acetate Drugs 0.000 claims abstract 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 230000003595 spectral effect Effects 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119043 | 2006-08-16 | ||
| EP06119043.5 | 2006-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009109352A true RU2009109352A (ru) | 2010-09-27 |
Family
ID=37685905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009109352/04A RU2009109352A (ru) | 2006-08-16 | 2007-08-14 | Кристаллическая форма эпотилона в и ее применение в фармацевтических композициях |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8178566B2 (enExample) |
| EP (1) | EP2064216A2 (enExample) |
| JP (1) | JP2010500387A (enExample) |
| KR (1) | KR20090038902A (enExample) |
| CN (1) | CN101506217B (enExample) |
| AR (1) | AR062375A1 (enExample) |
| AU (1) | AU2007286454A1 (enExample) |
| BR (1) | BRPI0715963A2 (enExample) |
| CA (1) | CA2658475A1 (enExample) |
| CL (1) | CL2007002362A1 (enExample) |
| IL (1) | IL196558A0 (enExample) |
| MA (1) | MA30656B1 (enExample) |
| MX (1) | MX2009001635A (enExample) |
| MY (1) | MY148355A (enExample) |
| NO (1) | NO20091081L (enExample) |
| NZ (1) | NZ574194A (enExample) |
| PE (1) | PE20081317A1 (enExample) |
| RU (1) | RU2009109352A (enExample) |
| TN (1) | TN2009000044A1 (enExample) |
| TW (1) | TW200815455A (enExample) |
| WO (1) | WO2008019820A2 (enExample) |
| ZA (1) | ZA200900227B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011146638A1 (en) | 2010-05-18 | 2011-11-24 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| CN103910742B (zh) * | 2013-01-07 | 2016-07-13 | 浙江海正药业股份有限公司 | 一种制备埃博霉素b无定形粉末的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1052974B1 (en) | 1998-02-05 | 2009-05-20 | Novartis AG | Pharmaceutical formulation containing epothilone |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
| BRPI0314133A8 (pt) * | 2002-09-23 | 2017-09-19 | Bristol Myers Squibb Co | Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona |
-
2007
- 2007-08-14 BR BRPI0715963-3A patent/BRPI0715963A2/pt not_active IP Right Cessation
- 2007-08-14 JP JP2009524113A patent/JP2010500387A/ja active Pending
- 2007-08-14 RU RU2009109352/04A patent/RU2009109352A/ru not_active Application Discontinuation
- 2007-08-14 AU AU2007286454A patent/AU2007286454A1/en not_active Abandoned
- 2007-08-14 CA CA002658475A patent/CA2658475A1/en not_active Abandoned
- 2007-08-14 CN CN2007800304132A patent/CN101506217B/zh not_active Expired - Fee Related
- 2007-08-14 US US12/376,973 patent/US8178566B2/en not_active Expired - Fee Related
- 2007-08-14 MY MYPI20090415A patent/MY148355A/en unknown
- 2007-08-14 KR KR1020097002958A patent/KR20090038902A/ko not_active Ceased
- 2007-08-14 NZ NZ574194A patent/NZ574194A/en not_active IP Right Cessation
- 2007-08-14 AR ARP070103603A patent/AR062375A1/es not_active Application Discontinuation
- 2007-08-14 EP EP07801648A patent/EP2064216A2/en not_active Withdrawn
- 2007-08-14 WO PCT/EP2007/007173 patent/WO2008019820A2/en not_active Ceased
- 2007-08-14 CL CL200702362A patent/CL2007002362A1/es unknown
- 2007-08-14 PE PE2007001090A patent/PE20081317A1/es not_active Application Discontinuation
- 2007-08-14 MX MX2009001635A patent/MX2009001635A/es not_active Application Discontinuation
- 2007-08-15 TW TW096130206A patent/TW200815455A/zh unknown
-
2009
- 2009-01-12 ZA ZA2009/00227A patent/ZA200900227B/en unknown
- 2009-01-15 IL IL196558A patent/IL196558A0/en unknown
- 2009-02-13 TN TN2009000044A patent/TN2009000044A1/fr unknown
- 2009-02-20 MA MA31654A patent/MA30656B1/fr unknown
- 2009-03-11 NO NO20091081A patent/NO20091081L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2007002362A1 (es) | 2008-08-08 |
| AU2007286454A1 (en) | 2008-02-21 |
| MY148355A (en) | 2013-03-29 |
| CN101506217B (zh) | 2012-09-05 |
| WO2008019820A3 (en) | 2008-04-17 |
| IL196558A0 (en) | 2009-11-18 |
| TN2009000044A1 (en) | 2010-08-19 |
| US8178566B2 (en) | 2012-05-15 |
| WO2008019820A2 (en) | 2008-02-21 |
| NO20091081L (no) | 2009-03-16 |
| AR062375A1 (es) | 2008-11-05 |
| BRPI0715963A2 (pt) | 2013-08-06 |
| KR20090038902A (ko) | 2009-04-21 |
| JP2010500387A (ja) | 2010-01-07 |
| CN101506217A (zh) | 2009-08-12 |
| NZ574194A (en) | 2011-12-22 |
| PE20081317A1 (es) | 2008-10-28 |
| TW200815455A (en) | 2008-04-01 |
| MA30656B1 (fr) | 2009-08-03 |
| CA2658475A1 (en) | 2008-02-21 |
| US20100160393A1 (en) | 2010-06-24 |
| EP2064216A2 (en) | 2009-06-03 |
| ZA200900227B (en) | 2009-12-30 |
| MX2009001635A (es) | 2009-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA023646B1 (ru) | Замещённые соли 2,3-дигидроимидазо[1,2-c]хиназолина | |
| JP2018534321A (ja) | がんを治療するための四環式キノロン類似体の併用療法 | |
| RU2013108641A (ru) | Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах | |
| RU2018120318A (ru) | ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| EP3310783B1 (en) | Compositions for the prevention of hearing loss | |
| JP2019514854A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| ES2550227T1 (es) | Procedimiento para preparar una composición farmacéutica en forma de comprimidos de liberación prolongada que contiene pirfenidona y su utilización en la regresión de la insuficiencia renal crónica, la contractura capsular mamaria, y la fibrosis hepática en humanos | |
| NO20076195L (no) | Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer | |
| RU2008145714A (ru) | Пуриновые производные в качестве активатора аденозинового рецептора | |
| RU2011145054A (ru) | Кристаллические формы саксаглиптина | |
| RU2003133213A (ru) | Кристаллическая форма омепразола | |
| RU2016136351A (ru) | Пиррол-замещенное производное индолона, способ его получения, включающая его композиция и применение | |
| RU2006128788A (ru) | Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов | |
| RU2009109352A (ru) | Кристаллическая форма эпотилона в и ее применение в фармацевтических композициях | |
| ES2355526T3 (es) | Métodos y composiciones que usan compuestos inmunomoduladores para el tratamiento de trastornos asociados a niveles de leptina en plasma bajos. | |
| EP4349340A1 (en) | Use of pharmaceutical composition for treating lung cancer | |
| RU2006138035A (ru) | Применение производного фенотиазина для профилактики и/или лечения потери слуха | |
| RU2008127260A (ru) | Производные хиназолинона в качестве антагонистов ваниллоидов | |
| CN111971283A (zh) | 具有增强的抗肿瘤作用的新型化合物 | |
| RU2004120529A (ru) | Способ лечения диабетической ретинопатии | |
| JP2015531355A (ja) | 腫瘍治療のための薬剤組成物及びその適用 | |
| RU2008100036A (ru) | Кристаллические формы производного пирролотриазина | |
| RU2012123970A (ru) | Тивозаниб и темсиролимус в комбинации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20120625 |